New Trends in Radioiodine Treatment for the Advanced Differentiated Thyroid Cancer
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Iodine-131 (I-131) has been used in the therapy of well-differentiated thyroid cancer for over 60 years and has been an important component in the management of well-differentiated thyroid cancer. Differentiated thyroid carcinoma (DTC) is one of the most curable cancers, associated with a 10-year survival rate of 80∼95%. Total (or near-total) thyroidectomy followed by radioiodine ablation is considered to be the ideal treatment for the high risk tumors. The selective use of radioactive iodine on the basis of clinicopathologic features that define the risk of recurrence and disease specific mortality is generally recommended in many kinds of international or institutional guidelines. However, recurrence in the thyroid bed or cervical lymph nodes develops in 5∼20% of patients with DTC and some patients develop distant metastatic disease decreasing the 10- year survival of patients by 50%. Unfortunately, many of these patients ultimately die from advanced disease and other therapeutic approaches are needed. The goals of therapy for those patients should be to improve survival, relieve symptoms, and decrease the morbidity of disease progression and limit the morbidity associated with therapy. Safe practice of radioiodine treatment should be balanced with the benefit and the risk. This review will address the results of the radioiodine treatments in patients with the advanced thyroid cancer with the recent clinical trials. (Korean J Endocrine Surg 2011;11:139-145)
Abstract
Iodine-131 (I-131) has been used in the therapy of well-differentiated thyroid cancer for over 60 years and has been an important component in the management of well-differentiated thyroid cancer. Differentiated thyroid carcinoma (DTC) is one of the most curable cancers, associated with a 10-year survival rate of 80∼95%. Total (or near-total) thyroidectomy followed by radioiodine ablation is considered to be the ideal treatment for the high risk tumors. The selective use of radioactive iodine on the basis of clinicopathologic features that define the risk of recurrence and disease specific mortality is generally recommended in many kinds of international or institutional guidelines. However, recurrence in the thyroid bed or cervical lymph nodes develops in 5∼20% of patients with DTC and some patients develop distant metastatic disease decreasing the 10- year survival of patients by 50%. Unfortunately, many of these patients ultimately die from advanced disease and other therapeutic approaches are needed. The goals of therapy for those patients should be to improve survival, relieve symptoms, and decrease the morbidity of disease progression and limit the morbidity associated with therapy. Safe practice of radioiodine treatment should be balanced with the benefit and the risk. This review will address the results of the radioiodine treatments in patients with the advanced thyroid cancer with the recent clinical trials. (Korean J Endocrine Surg 2011;11:139-145)
참고문헌 (35)
- Sampson E, "Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis", Cancer, 110, pp.1451~1456 (2007)
- Shaha AR, "Differentiated thyroid cancer presenting initially with distant metastasis", Am J Surg, 174, pp.474~476 (1997)
- Haq MS, "Non-surgical management of thyroid cancer, In Practical Management of Thyroid Cancer", pp.171~191 (2006), Springer
- Haugen BR, "Approach to the thyroid cancer patient with extracervical metastases", J Clin Endocrinol Metab, 95, pp.987~993 (2010)
- Seidlin SM, "Radioactive iodine therapy; effect on functioning metastases of adenocarcinoma of the thyroid", J Am Med Assoc, 132, pp.838~847 (1946)
- Van Nostrand D, "The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer", Thyroid, 19, pp.1381~1391 (2009)
- Muresan MM, "Bone metastases from differentiated thyroid carcinoma", Endocr Relat Cancer, 15, pp.37~49 (2008)
- Haigh PI, "Extent of thyroidectomy is not a major determinant of survival in low- or high-risk papillary thyroid cancer", Ann Surg Oncol, 12, pp.81~89 (2005)
- Haq M, "Differentiated thyroid carcinoma with distant metastases at presentation: prognostic factors and outcome", Clin Endocrinol (Oxf), 63, pp.87~93 (2005)
- Qiu ZL, "Erector spinae metastases from differentiated thyroid cancer identified by I-131 SPECT", CT, 2009, pp.34, 137~140
- Sherman SI, "Prospective multicenter study of thyrois carcinoma treatment: initial analysis of staging and outcome", Cancer, 83, pp.1012~1021 (1998), National Thyroid Cancer Treatment Cooperative Study Registry Group
- Sampson E, "Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis", Cancer, 110, pp.1451~1456 (2007)
- Taylor T, "Outcome after treatment of high-risk papillary and non-Hürthle-cell follicular thyroid carcinoma", Ann Intern Med, 129, pp.622~627 (1998)
- Van Nostrand D, "Radioiodine treatment of distant metastases, In Thyroid Cancer: A Comprehensive Guide to Clinical Management. 2nd ed", pp.411~427 (2006), Humana Press
- Massin JP, "Pulmonary metastases in differentiated thyroid carcinoma. Study of 58 cases with implications for the primary tumor treatment", Cancer, 53, pp.982~992 (1984)
- Schlumberger M, "Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays", J Nucl Med, 29, pp.1790~1794 (1988)
- fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer, "J Clin Endocrinol Metab", 2000, 1107~1113
- Joensuu H, "Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose", J Nucl Med, 28, pp.910~914 (1987)
- Chiu AC, "Prognosis and treatment of brain metastases in thyroid carcinoma", J Clin Endocrinol Metab, 82, pp.3637~3642 (1997)
- McWilliams RR, "Management of brain metastases from thyroid carcinoma: a study of 16 pathologically confirmed cases over 25 years", Cancer, 98, pp.356~362 (2003)
- Chao M, "Management of differentiated thyroid cancer with rising thyroglobulin and negative diagnostic radioiodine whole body scan", Clin Oncol (R Coll Radiol), 22, pp.438~447 (2010)
- Alzahrani AS, "Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer", J Endocrinol Invest, 28, pp.540~546 (2005)
- Gutiérrez Cardo AL, "Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course", Rev Esp Med Nucl, 26, pp.138~145 (2007)
- Ma C, "Possible explanations for patients with discordant findings of serum thyroglobulin and 131I whole-body scanning", J Nucl Med, 46, pp.1473~1480 (2005)
- Schlumberger MJ, "Papillary and follicular thyroid carcinoma", N Engl J Med, 338, pp.297~306 (1998)
- Schlumberger M, "Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays", J Nucl Med, 29, pp.1790~1794 (1988)
- Ozata M, "Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer", J Clin Endocrinol Metab, 79, pp.98~105 (1994)
- Bertagna F, "Role of 18F-fluorodeoxyglucose positron emission tomography", computed tomography in patients affected by differentiated thyroid carcinoma, high thyroglobulin level, and negative 131I scan: review of the literature, 2010, pp.28, 629~636
- fluoro-2-deoxy-D-glucose-positron emission tomography scanning, "J Clin Endocrinol Metab", 2006, 498~505
- Schönberger J, "Glucose transporter 1 gene expression is related to thyroid neoplasms with an unfavorable prognosis: an immunohistochemical study", Thyroid, 12, pp.747~754 (2002)
- Melck AL, "The utility of BRAF testing in the management of papillary thyroid cancer", Oncologist, 15, pp.1285~1293 (2010)
- Feine U, "18FDG whole-body PET in differentiated thyroid carcinoma. Flipflop in uptake patterns of 18FDG and 131I", Nuklearmedizin, 34, pp.127~134 (1995)
- Feine U, "Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer", J Nucl Med, 37, pp.1468~1472 (1996)
- McDougall IR, "Positron emission tomography of the thyroid, with an emphasis on thyroid cancer", Nucl Med Commun, 22, pp.485~492 (2001)
- Khan N, "PET in the follow-up of differentiated thyroid cancer", Br J Radiol, 76, pp.690~695 (2003)